Communiqués SciSparc Ltd.

Actions

SPRC

IL0010951403

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:30:00 04/09/2026			Varia. 5j.	Varia. 1 janv.
5,290 ^USD	+3,12%		-19,60%	-56,78%

26/08	SciSparc Ltd. annonce la nomination du professeur Carmel Domshlak au sein de son conseil consultatif scientifique pour l'IA et la cybersécurité, à compter du 1er septembre 2026	CI
05/08	SciSparc Ltd. lance un essai clinique de phase IIb au Yale Child Study Center pour le SCI-110 dans le traitement du syndrome de la Tourette	CI

Communiqués

02/09	SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies	GL
31/08	SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial	GL
26/08	SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board	GL
24/08	SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation	GL
19/08	SciSparc : Amendment to Annual Report by Foreign Issuer (Form 20-F/A)	PU
18/08	SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million	PU
18/08	SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million	GL
12/08	SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination	GL
05/08	SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome	GL
31/07	SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics	GL
30/07	SciSparc, Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company	AQ
29/07	SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company	GL
27/07	SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity	GL
15/07	SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome	GL
05/06	SciSparc, Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum	AQ
04/06	SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum	GL
28/05	SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum	GL
16/03	SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy	GL
12/03	SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease	GL
11/03	SciSparc, Subsidiary NeuroThera Labs Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails	AQ
10/03	SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails	GL
02/03	SciSparc Announces 1-for-9 Reverse Share Split	GL
02/02	SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA	GL
26/01	SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization	GL
13/01	SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity	GL